Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Conclusion: ALBI grade appeared to be prognostic for o utcomes with both atezolizumab + bevacizumab and sorafenib treatment in patients with HCC. Atezolizumab + bevacizumab preserved liver function for a numerically longer duration than sorafenib.
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
More News: Avastin | Bilirubin | Cancer | Cancer & Oncology | Carcinoma | Children | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Urology & Nephrology